News & Blog

Ozyuvali E, Yildirim ME, Yaman T, Kosem B, Cimentepe E. Protective Effect of Intravesical Platelet-Rich Plasma on Cyclophosphamide-Induced Hemorrhagic Cystitis. Clin Invest Med. 2016 Dec 1;39(6):27524.

Although a recent basic research study suggested that intravesical instillation of platelet-rich plasma (PRP) could be a promising future therapy for patients with interstitial cystitis/bladder pain syndrome (IC/BPS), not all evidence is pointing in the same direction. Platelet-rich plasma (PRP) is produced from the subject’s own blood, which is withdrawn and processed to isolate a platelet-rich extract, which is then reintroduced to the body. In the previous study, rabbits with an induced, experimental form of IC were treated with intravesical PRP, which reduced visible bleeding, and increased the mitotic index, which suggested tissue regeneration. However, in this more recent study, female rats were injected with a substance used to induce IC, and some also received intravesical PRP. Investigators found that PRP in fact did not suppress the swelling, bleeding, and inflammation caused by the IC. This finding underscores the need for more study of PRP as a potential treatment for IC.